Company Profile
——
Guangzhou Sinogen Pharmaceutical Co., Ltd. is a biotechnology company committed to the development and production of innovative biological oncology drugs to meet the global demand for the treatment of a broad malignant tumors.
Since its establishment in 2016, under the leadership of Dr. Allan Zhao and other three nationally distinguished experts, and through the joint efforts of dozens of researchers, the company has gradually established the world's first rapid broad-spectrum oncolytic bacteria technology platform, and completed the preclinical study, the development of CMC manufacturing process, and the construction of GMP-compliant large-scale production facilities of the core product, an oncolytic bacteria, named as SalMet-Vec . Our first-in-class product SalMet-Vec has obtained the IND approvals from US FDA , Taiwan FDA and China NMPA, and has launched international multi-center phase I/IIa clinical trials for a variety of malignant solid tumors in the United States, Taiwan region and mainland China.
Honor
——
Milestones
——
Chairman's Speech
——
Thank you for visiting us! Sinogen is entering a new era of prosperous development!
In 2017, China's official announcement to join the International Council for Harmonisation (ICH) has enabled the country to rapidly transit from a generic drugs-dominated industry over the past decades to a new era aimed at developing global innovative medicines. Sinogen will seize such a rare opportunity and rise to the challenge with full confidence.
Sinogen was founded in 2016 by four nationally distinguished experts returning from the United States. They are biomedical experts with an international perspective and rich experiences in drug research and development, manufacturing quality control, regulatory affairs, and clinical trials. Since its establishment, the company has always persistently advocated for the spirit of innovation, committed itself to the research and development of innovative medicine with global intellectual property rights, and set the goal of breakthrough progress in the treatment of many difficult-to-treat cancers.
We have always promoted the concept of people-oriented working environment, continuous innovation, integrity, cooperation and sharing, and aspiring to be the leading pharmaceutical enterprise in China. We always look for and welcome ambitious people sharing our development philosophy to join hands with us in creating a brilliant future of Sinogen!
Leadership
Team
——
July 2016
The company was established in Guangzhou as a R&D biopharmaceutical company in July 2016
August 2017
The company obtained angel funding in August 2017
March 2020
The company obtained pre-series A funding in March 2020
September 2020
The company obtained series A funding in September 2020
October 2020
SalMet-Vec obtained U.S. FDA's IND approval for intravenous injection in October 2020
March 2021
SalMet-Vec obtained U.S. FDA's IND approval for intratumoral injection in March 2021
November 2021
The U.S. phase I/IIa clinical trial of SalMet-Vec was formally launched in November 2021
November 2022
FDA granted orphan drug designation(ODD) to SalMet-Vec for the treatment of osteosarcoma
December 2022
FDA granted orphan drug designation(ODD) to SalMet-Vec for the treatment of hepatocellular carcinoma
February 2023
The first patient's intravenous administration of SalMet-Vec phase I/IIa clinical trial was completed in the United States
March 2023
The first patient's intratumoral administration of SalMet-Vec phase I/IIa clinical trial was completed in Taiwan, China
®
®
®
®
®
August 2023
FDA granted orphan drugdesignation(ODD) to
SalMet-Vec for the treatment
of Small Cell Lung Cancer
®
September 2023
SalMet-Vec obtained two IND approvals for intravenous infusion and intratumoral injection of NMPA CDE.
®
June 2021
The P2 laboratory and manufacturing workshop were inaugurated in Guangzhou in June 2021
May 2022
Pre-B round of financing completed
®
®
®
®
Guangzhou Sinogen Pharmaceutical Co.,Ltd.all rights reserved 粤ICP备20063851号
Address:Room 101, 1st Floor, Building C5, Science and Technology Enterprise Accelerator, Huangpu District, Guangzhou Email : sinogen@sinogen.cc Service Time : Work days 9:00 ~ 17:00
Science&Prouduct
Contact Us
sinogen@sinogen.cc
Work days 9: 00 ~17: 00
Address:Room 101, 1st Floor, Building C5,
Science and Technology Enterprise Accelerator,
Huangpu District, Guangzhou
Investor Relations
Careers